Chemotherapeutic Management of Non-Hodgkin’s Lymphoma: Comparative Study of Various Combinations

Summary

74 patients with non-Hodgkin’s lymphoma attending the Medical Oncology Dept., Cancer Institute, Cairo University, received at random two regimens of combination chemotherapy. The group who received MOPP achieved 60%, while the group receiving CPP achieved 56% CR.

Although malignant lymphoma patients represent 7.8% of those attending the Cairo Cancer Institute annually, yet amongst those attending the Medical Oncology Dept.: Medical and Pediatric Units, it stands the first.

Non-Hodgkin’s lymphoma cases are more prevalent than Hodgkin’s cases. Thus, in the year 1973, amongst 281 cases of malignant lymphoma attending the Cairo Cancer Institute, 127 were of the Non-Hodgkin’s type, with the lymphocytic type predominating.

Chemotherapeutic management of Non-Hodgkin’s lymphoma still poses an international problem. For us, its management is of particular importance due to its prevalence together with the fact that we usually deal with advanced stages : III & IV. 75% of our cases belong to stage IV. Moreover, the diffuse type is more prevalent than the nodular type.

The present study evaluates the results of combination chemotherapy in patients with Non-Hodgkin’s lymphoma.